Bayer stock: FDA approval opens new market for Sunharbo

Bayer's U.S. approval of Sunharbo creates a new commercial opportunity in secondary stroke prevention, although the launch remains ahead of the first shipments. Bayer announced the FDA decision on November 9, 2026, and expects the medicine to reach U.S. hospitals and pharmacies in mid-to-late November, according to the company's FDA approval announcement.

Approval opens a new class

Sunharbo, the brand name for asundexian, is the first Factor XIa inhibitor approved in the United States. The once-daily 50-milligram tablet is indicated with antiplatelet therapy for adults after a recent non-cardioembolic ischemic stroke or a high-risk transient ischemic attack.

The approval gives Bayer a product in a mechanism distinct from established Factor Xa inhibitors. That matters commercially as the company manages pressure on its older anticoagulant Xarelto from generic competition. The initial opportunity is tied to a defined secondary-prevention population rather than the broader market for blood thinners.

Trial results support the launch

The FDA decision was based on the Phase 3 OCEANIC-STROKE study, which randomized 12,327 patients. Ischemic strokes occurred in 6.2 percent of patients receiving Sunharbo and antiplatelet therapy, compared with 8.4 percent in the placebo and antiplatelet group, a relative reduction of 26 percent.

Bayer reported similar rates of major bleeding between the two groups, while gastrointestinal bleeding was higher with Sunharbo. These safety findings will remain important for physicians and payers as the company moves from regulatory approval to commercial adoption.

Launch execution is next

Bayer expects U.S. shipments to start in mid-to-late November. The company says Sunharbo is under review by the European Medicines Agency and Japan's Ministry of Health, Labour and Welfare; China approved the medicine on October 26.

For investors, early prescription uptake, payer access and the breadth of use among stroke specialists will shape how quickly the approval contributes to Bayer's Pharmaceuticals business.

For broader German market developments, see Current market reports.

Further news and analysis on the company are available under More news and analyses on Bayer stock.